Korean Journal of Community Nutrition (대한지역사회영양학회지)

The Korean Society of Community Nutrition (대한지역사회영양학회)
권호 표지
DOI QR코드

DOI QR Code

Association of Plasma Osteoprotegerin with Adiponectin and Difference according to Obesity in Men with Metabolic Syndrome

대사증후군 남성에서의 혈중 Osteoprotegerin의 아디포넥틴과의 상관성과 비만도에 따른 차이

  • 나우리 (원광대학교 식품영양학전공) ;
  • 손정민 (원광대학교 식품영양학전공)
  • Received : 2011.11.10
  • Accepted : 2011.12.05
  • Published : 2011.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Osteoprotegerin (OPG) plays a core role in bone reformation by antagonizing the effect of receptor activator of nuclear factor ${\kappa}$-B ligand (RANKL), and mediates vascular calcification in cardiovascular disease patients. Thus, we aimed to examine the relationship between serum OPG levels and cardiovascular factors and inflammatory markers in metabolic syndrome patients (MS). This cross-sectional study included 96 men who visited the diet clinic between May and July 2011. Patients were classified into 2 groups based on NCEP-ATP guidelines: normal and with MS (n = 50 and 46, respectively). Physical measurements, biochemical assay were measured. Serum OPG and IL-6, diponectin and hs-CRP were assessed. MS were aged $50.02{\pm}10.85$ years, and normal patients $52.07{\pm}9.56$ years, with no significant differences. Significant differences were not observed in BMI between the 2 groups. Moreover, significant differences were not observed in serum OPG, however, the serum OPG level ($4.41{\pm}1.86pmol/L$) differed significantly between an overweight MS (BMI > 25) and normal patients. OPG was correlated to age (r = 0.410, p = 0.000), HDL-cholesterol (r = 0.209, p = 0.015), and log adiponectin (r = 0.175, p = 0.042). Multiple regression analyses using the enter method showed that age (${\beta}$ = 0.412, p = 0.000) and BMI (${\beta}$ = 0.265, p = 0.000) considerably affected OPG. In conclusion, out study showed that serum OPG levels are correlated with cardiovascular risk factors, such as BMI, HDL-cholesterol and adiponectin in MS and adiponectin, suggesting that serum OPG has potential as a cardiovascular disease indicator and predictor.

Keywords

References

  1. Altinova AE, Toruner F, Akturk M, Bukan N, Yetkin I, Cakir N, Arslan M (2011): Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. Scand J Clin Lab Invest 71(4): 340-343 https://doi.org/10.3109/00365513.2011.570868
  2. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R (2006): The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 47(9): 1850-1857 https://doi.org/10.1016/j.jacc.2005.12.054
  3. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999): Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83 https://doi.org/10.1006/bbrc.1999.0255
  4. Ashley DT, O'Sullivan EP, Davenport C, Devlin N, Crowley RK, McCaffrey N, Moyna NM, Smith D, O'Gorman DJ (2011): Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. Metabolism 60(7): 994-1000 https://doi.org/10.1016/j.metabol.2010.10.001
  5. Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM (2005): Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 28: 2176-2180 https://doi.org/10.2337/diacare.28.9.2176
  6. Bae YJ, Kim MH (2010): Calcium and magnesium supplementation improves serum OPG/RANKL in calcium-deficient ovariectomized rats. Calcif Tissue Int 87(4): 365-372 https://doi.org/10.1007/s00223-010-9410-z
  7. Berk BC, Weintraub WS, Alexander RW (1990): Elevation of Creactive protein in "active" coronary artery disease. Am J Cardiol 65(3): 168-172 https://doi.org/10.1016/0002-9149(90)90079-G
  8. Browner WS, Lui LY, Cummings SR (2001): Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86(2): 631-637 https://doi.org/10.1210/jc.86.2.631
  9. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu WL, Lacey DL, Boyle WJ, Simonet WS (1998): Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12(9): 1260- 1268 https://doi.org/10.1101/gad.12.9.1260
  10. Chen WJ, Rijzewijk LJ, van der Meer RW, Heymans MW, van Duinkerken E, Lubberink M, Lammertsma AA, Lamb HJ, de Roos A, Romijn JA, Smit JW, Bax JJ, Bjerre M, Frystyk J, Flyvbjerg A, Diamant M (2011): Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol 10(1): 67[Epub ahead of print] https://doi.org/10.1186/1475-2840-10-67
  11. Coetzee M, Haag M, Kruger MC (2007): Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E2 and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells. J Nutr Biochem 18(1): 54-63 https://doi.org/10.1016/j.jnutbio.2006.03.002
  12. Esposito K, MarfellaR, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D (2004): Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292(12): 1440-1446 https://doi.org/10.1001/jama.292.12.1440
  13. Feingold KR, Grunfeld C (1992): Role of cytokines in inducing hyperlipidemia. Diabetes 41(2): 97-101
  14. Friedewald WT, Levy RI, Fredrickson DS (1972): Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6): 499-502
  15. Gannage-Yared MH, Fares F, Semaan M, Khalife S, Jambart S (2006): Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol 64(6): 652-658 https://doi.org/10.1111/j.1365-2265.2006.02522.x
  16. Gannage-Yared MH, Yaghi C, Habre B, Khalife S, Noun R, Germanos-Haddad M, Trak-Smayra V (2008): Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol 158(3): 353-359 https://doi.org/10.1530/EJE-07-0797
  17. Hong YM, Song YW, Kim HS, Park HS, Min JH, Jung JW, Kim NS, Noh CI (2009): Metabolic syndrome in the overweight and obese adolescents and the impact of obesity on the cardiovascular system. Korean J Pediatr 52(10): 1109-1118 https://doi.org/10.3345/kjp.2009.52.10.1109
  18. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y (2000): Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20(6): 1595-1599 https://doi.org/10.1161/01.ATV.20.6.1595
  19. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y (2002): Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106(10): 1192-1194 https://doi.org/10.1161/01.CIR.0000031524.49139.29
  20. Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson JE, Ehrlich J, Eckel RH, Rewers M (2005): Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 111(6): 747-753 https://doi.org/10.1161/01.CIR.0000155251.03724.A5
  21. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y (2002): Diet-induced insulin resistance in mice lacking adiponectin/ ACRP30. Nat Med 8: 731-737 https://doi.org/10.1038/nm724
  22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985): Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7): 412-419 https://doi.org/10.1007/BF00280883
  23. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS (2000): Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192(4): 463-474 https://doi.org/10.1084/jem.192.4.463
  24. Nabipour I, Kalantarhormozi M, Larijani B, Assadi M, Sanjdideh Z (2010): Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism 59(5): 742-747 https://doi.org/10.1016/j.metabol.2009.09.019
  25. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C, Feingold KR (1995): Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 136(5): 2143-2149 https://doi.org/10.1210/en.136.5.2143
  26. O'Sullivan EP, Ashley DT, Davenport C, Devlin N, Crowley R, Agha A, Thompson CJ, O'Gorman D, Smith D (2010): Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes. Diabetes Metab Res Rev 26(6): 496-502 https://doi.org/10.1002/dmrr.1109
  27. Park JY, Kim JW, Kim JM, Han Y, Park SK, Mok JY, Park MK, Lee HJ, Kim DK (2008): Adiponectin Concentrations in Type 2 Diabetic Patients with or without Metabolic Syndrome. Korean Diabetes J 32(3): 224-235 https://doi.org/10.4093/kdj.2008.32.3.224
  28. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001): Creactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286(3): 327-334 https://doi.org/10.1001/jama.286.3.327
  29. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000): C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342(12): 836- 843 https://doi.org/10.1056/NEJM200003233421202
  30. Rude RK, Gruber HE, Wei LY, Frausto A (2005): Immunolocalization of RANKL is increased and OPG decreased during dietary magnesium deficiency in the rat. Nutr Metab(Lond) 2(1): 24
  31. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC (2003): Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88(3): 1024-1028 https://doi.org/10.1210/jc.2002-020775
  32. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997): Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2): 309-319 https://doi.org/10.1016/S0092-8674(00)80209-3
  33. Stenvinkel P, Heimburger O, Jogestrand T (2002): Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: Association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis 39(2): 274-282 https://doi.org/10.1053/ajkd.2002.30546
  34. Wu XY, Wu XP, Xie H, Zhang H, Luo XH, Liu SP, Peng YQ, Dai RC, Liao EY (2008): Relationship between age-related reference values of serum osteoprotegerin and leptin in native Chinese women and compared with those in women of other races. Clin Chim Acta 389(1-2): 72-78 https://doi.org/10.1016/j.cca.2007.11.024